Drug Profile
Research programme: stapled peptide therapeutics - Aileron Therapeutics
Alternative Names: ATSP-9172; BID-BH3; BIDsp; BIM-BH3; BIM-SAHB; BIMspLatest Information Update: 16 Jul 2016
Price :
$50
*
At a glance
- Originator Aileron Therapeutics
- Class Peptides
- Mechanism of Action Apoptosis stimulants; Hypoxia-inducible factor-1 alpha inhibitors; Proto-oncogene protein c-bcl-2 modulators
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- No development reported Cancer; Multiple myeloma
Most Recent Events
- 16 Jul 2016 No recent reports of development identified for preclinical development in Cancer in USA (Parenteral)
- 16 Jul 2016 No recent reports of development identified for preclinical development in Multiple-myeloma in USA (Parenteral)
- 10 Apr 2013 Pharmacodynamics and pharmacokinetics data from a preclinical trial in Cancer presented at the 104th Annual Meeting of the American Association for Cancer Research (AACR-2013)